Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn's disease, and fistulizing crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating breast cancer; and GB492, a stimulator of interferon genes in combination with GB226, which is under Phase 1/2 clinical trial to treat solid tumors. It also develops GB226, which is in Phase III clinical trial to treat 2L+ cervical cancer; in phase II trial to treat ASPS and r/r PMBCL; and in Phase I trial to treat 2L/3L+ EGFR+ NSCLC and 2L+ mCRC. In addition, the company develops GB261, which is in Phase I/II clinical trial to treat NHL; and GB263T that is in Phase I/II clinical trial to treat NSCLC. Further, it develops GB221, which is in Phase III clinical trial for the treatment of HER2 + 1L/2L+ mBC; GB223 that is in Phase I clinical trial to treat GCTB and PMO; GB241, which is in Phase III clinical trial to treat 1L DLBCL; and GB251 that is in Phase I clinical trial to treat HER2 + 1L/2L+ mBC. Additionally, the company's product candidates under pre-clinical trials include GB262, GB264, GB266, GB267, and GB268 for the treatment of cancer. The company was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China. Address: Building 6, Shanghai, China, 201203